The drug, tofacitinib citrate, sold under the brand name Xeljanz, treats rheumatoid arthritis. It’s a JAK inhibitor, so-called because it inhibits an enzyme in the class of Janus kinases, mainly found in blood-forming cells. Doctors have been testing the drug for other diseases.
Tofacitinib is effective against hair loss called by alopecia universalis, according to a study by Dr. Brett King of Yale published last year. A man with almost no body hair grew a full head of hair after being treated with the drug, according to the study.
King and Dr. Brittany Craiglowe, coauthors of the new study in JAMA Dermatology, tested the drug against vitiligo in a 53-year-old woman whose facial, hand and body skin was covered with a growing number of white spots. Treatment with other drugs had been ineffective.
“After 2 months of therapy, partial repigmentation of the face and upper extremities was evident,” the study stated. “After 5 months, repigmentation of the forehead and hands was nearly complete, and the remaining involved areas demonstrated partial repigmentation. Approximately 5 percent of the total body surface area remained depigmented.”
There were no adverse effects from the drug, the study stated.
Extracts from a San Diego Union-Tribune article (original). Published 24 June 2015.
Also read ‘For vitiligo patient, arthritis drug restores skin color‘ – Yale News